Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis
Authors:
- 23 November 2023
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 165 (2) , 301-312
Abstract
Purpose To explore the impact of intrathecal pemetrexed (IP) on the survival of lung adenocarcinoma (LUAC) patients with leptomeningeal metastasis (LM). Methods We analyzed patients with LUAC and LM who received systemic therapy after LM diagnosis at the Fujian Cancer Hospital between July 2018 and March 2022. Patients who underwent IP were assigned to the IP group; those without IP treatment were designated as the non-IP group. Propensity score matching (PSM) was performed between the two groups. Results 165 patients were enrolled: 83 and 82 in the IP and non-IP groups, respectively. After 1:1 PSM, we included 114 patients in the matched cohort. Median overall survival (OS) was 13.2 months (95% CI 10.8–15.6 months) in the IP group versus 10.1 months (95% CI 5.3–14.9 months) in the non-IP group (P = 0.488). Only Eastern Cooperative Oncology Group Performance Status (ECOG PS) was confirmed as an independent predictor for OS in the matched cohort (hazard ratio (HR) 2.03; P = 0.023). Multivariate competing-risks analysis showed that IP significantly correlated with central nervous system-related death (HR 0.31; P = 0.046). When stratified by ECOG PS, IP improved survival in patients with poor ECOG PS (PS = 2) (14.3 months vs. 1.6 months; P = 0.003). Conclusions Intrathecal pemetrexed did not enhance OS for the entire LUAC patient with LM compared to non-intrathecal chemotherapy. However, it exhibited the potential to reduce the risk of central nervous system-related mortality and improve survival in patients with poor ECOG PS.Keywords
Funding Information
- Natural Science Foundation of Fujian Province (2023J01180)
- Fujian Provincial Health Technology Project (2022QNA046)
- Startup Fund for Scientific Research of Fujian Medical University (2020QH1218)
- National Natural Science Foundation of China (82072565)
- Fujian Provincial Health Systemic Innovation Project (2020CXA010)
This publication has 26 references indexed in Scilit:
- Leptomeningeal metastases in non-small-cell lung cancerThe Lancet Oncology, 2018
- Response Assessment in Neuro-Oncology Clinical TrialsJournal of Clinical Oncology, 2017
- EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumoursAnnals of Oncology, 2017
- Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trialsNeuro-Oncology, 2014
- Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain RadiotherapyJournal of Thoracic Oncology, 2012
- Safety and pharmacokinetics of intrathecal administration of pemetrexed in ratsCancer Chemotherapy and Pharmacology, 2010
- The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised studyEuropean Journal of Cancer, 2004
- A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.1999
- Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.Journal of Clinical Oncology, 1993
- A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis.Journal of Clinical Oncology, 1987